WO2000073430A3 - Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind - Google Patents

Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind Download PDF

Info

Publication number
WO2000073430A3
WO2000073430A3 PCT/DE2000/001809 DE0001809W WO0073430A3 WO 2000073430 A3 WO2000073430 A3 WO 2000073430A3 DE 0001809 W DE0001809 W DE 0001809W WO 0073430 A3 WO0073430 A3 WO 0073430A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
antigens
conformation
peptides
proteins
Prior art date
Application number
PCT/DE2000/001809
Other languages
English (en)
French (fr)
Other versions
WO2000073430A2 (de
Inventor
Steffen Goletz
Uwe Karsten
Original Assignee
Max Delbrueck Centrum
Steffen Goletz
Uwe Karsten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Steffen Goletz, Uwe Karsten filed Critical Max Delbrueck Centrum
Priority to CA002375033A priority Critical patent/CA2375033A1/en
Priority to AU64243/00A priority patent/AU6424300A/en
Priority to EP00951201A priority patent/EP1181058A2/de
Publication of WO2000073430A2 publication Critical patent/WO2000073430A2/de
Publication of WO2000073430A3 publication Critical patent/WO2000073430A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die Erfindung betrifft ein Verfahren, das es erlaubt, die hocheffektive Technologie der Vakzinierung mittels Desoxyribonukleinsäure (DNA) nicht nur auf Sequenzepitope von Proteinen oder Peptiden, sondern auch auf Konformationsepitope anzuwenden. Dieses Verfahren ermöglicht darüber hinaus die Nutzung der DNA-Vakzinierung auch bei solchen Antigenen, die keine oder nur teilweise Proteine oder Peptide sind. Die bevorzugte erfindungsgemässe Vakzine enthält als wesentlichen Bestandteil eine Desoxyribonukleinsäure (DNA), die eine Peptidsequenz kodiert, welche ihrerseits die immunologische Imitation (Mimikry) eines konformationsabhängigen Antigens einschließlich Protein-Konformationsepitope oder eines Antigens, das kein oder nur teilweise Protein oder Peptid ist, darstellt. Das Mimikry-Peptid, das ebenfalls Teil der erfindungsgemäßen Vakzine ist oder sein kann, ist entweder ein antiidiotypischer Antikörper, ein Antikörperfragment, ein daraus abgeleitetes Peptid oder ein durch Selektion aus einer Peptid-Genbank erhaltenes spezifisch bindendes Peptid. Anwendungsgebiete der Erfindung sind die medizinische und die veterinärmedizinische Immunologie, darunter die adjuvante Therapie von Tumorerkrankungen.
PCT/DE2000/001809 1999-05-27 2000-05-29 Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind WO2000073430A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002375033A CA2375033A1 (en) 1999-05-27 2000-05-29 Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
AU64243/00A AU6424300A (en) 1999-05-27 2000-05-29 Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
EP00951201A EP1181058A2 (de) 1999-05-27 2000-05-29 Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19924405.7 1999-05-27
DE19924405 1999-05-27
DE19943016.0 1999-09-09
DE19943016 1999-09-09

Publications (2)

Publication Number Publication Date
WO2000073430A2 WO2000073430A2 (de) 2000-12-07
WO2000073430A3 true WO2000073430A3 (de) 2001-03-29

Family

ID=26053552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/001809 WO2000073430A2 (de) 1999-05-27 2000-05-29 Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind

Country Status (5)

Country Link
EP (1) EP1181058A2 (de)
AU (1) AU6424300A (de)
CA (1) CA2375033A1 (de)
DE (1) DE10027695A1 (de)
WO (1) WO2000073430A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU8473401A (en) 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
KR20030093316A (ko) * 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
JP4485367B2 (ja) * 2002-12-03 2010-06-23 パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレイテッド プリオンタンパク質リガンドおよび使用方法
GB0324265D0 (en) * 2003-10-16 2003-11-19 Medical Res Council Peptide
PL1735347T3 (pl) 2004-03-29 2013-04-30 The Univ Court Of The Univ Of Aberdeen Specyficznie wiążące cząsteczki przeciwko synaptofizynie
BRPI0608468A2 (pt) * 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
EP1888640B1 (de) 2005-05-18 2012-03-14 Ablynx N.V. Verbesserte nanokörper gegen tumornekrosefaktor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CN1301267C (zh) * 2005-06-21 2007-02-21 中国人民解放军军事医学科学院附属医院 Muc1粘蛋白的一个模拟表位肽及其编码dna与应用
EP2245052B1 (de) 2008-01-25 2017-05-24 Aarhus Universitet Selektive exosite-inhibierung der papp-a-aktivität gegenüber igfbp-4
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
NZ623264A (en) 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508282A2 (de) * 1991-04-01 1992-10-14 Kyowa Hakko Kogyo Co., Ltd. Anti-idiotypische monoklonale Antikörper
WO1998000444A1 (de) * 1996-06-27 1998-01-08 Max-Delbrück-Centrum für Molekulare Medizin Vakzine gegen kohlenhydrat-antigene
WO1999040433A1 (en) * 1998-02-04 1999-08-12 The Trustees Of The University Of Pennsylvania Peptide mimotopes of carbohydrate antigens
WO1999054457A1 (en) * 1998-04-20 1999-10-28 Chiron S.P.A. Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508282A2 (de) * 1991-04-01 1992-10-14 Kyowa Hakko Kogyo Co., Ltd. Anti-idiotypische monoklonale Antikörper
WO1998000444A1 (de) * 1996-06-27 1998-01-08 Max-Delbrück-Centrum für Molekulare Medizin Vakzine gegen kohlenhydrat-antigene
WO1999040433A1 (en) * 1998-02-04 1999-08-12 The Trustees Of The University Of Pennsylvania Peptide mimotopes of carbohydrate antigens
WO1999054457A1 (en) * 1998-04-20 1999-10-28 Chiron S.P.A. Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
APOSTOLOPOULOS V ET AL: "Carbohydrate /peptide mimics: effect on MUC1 cancer immunotherapy.", JOURNAL OF MOLECULAR MEDICINE, (1999 MAY) 77 (5) 427-36. REF: 57, XP000960532 *
GOLLASCH H ET AL: "Identification of immunogenic peptide-mimics for the Thomsen-Friedenreich-glycoantigen.", ANNALS OF HEMATOLOGY, vol. 77, no. SUPPL. 2, 1998, Annual Congress of the German and Austrian Societies of Hematology and Oncology;Frankfurt, Germany; October 25-28, 1998, pages S84, XP000960533, ISSN: 0939-5555 *
KARSTEN UWE ET AL: "Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.", CANCER RESEARCH, vol. 58, no. 12, 15 June 1998 (1998-06-15), pages 2541 - 2549, XP002112486, ISSN: 0008-5472 *
LOSMAN M J ET AL: "MIMICRY OF A CARCINOEMBRYONIC ANTIGEN EPITOPE BY A RAT MONOCLONAL ANTI-IDIOTYPE ANTIBODY", INTERNATIONAL JOURNAL OF CANCER,US,NEW YORK, NY, vol. 56, no. 4, 15 February 1994 (1994-02-15), pages 580 - 584, XP000577759, ISSN: 0020-7136 *
PINILLA CLEMENCIA ET AL: "All-D peptides recognized by an anti-carbohydrate antibody identified from a positional scanning library.", JOURNAL OF MOLECULAR BIOLOGY, vol. 283, no. 5, 13 November 1998 (1998-11-13), pages 1013 - 1025, XP002152467, ISSN: 0022-2836 *
POTTER V ET AL: "DNA vaccination with A scFv of the anti-idiotype antibody 105Ad7 induces a TH1 immune response.", BRITISH JOURNAL OF CANCER, vol. 78, no. SUPPL. 2, 1998, Joint Meeting of the British Oncological Association, the Association of Cancer Physicians and the Royal College of Radiologists;Nottingham, England, UK; July 5-7, 1998, pages 18, XP000960534, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
AU6424300A (en) 2000-12-18
CA2375033A1 (en) 2000-12-07
EP1181058A2 (de) 2002-02-27
DE10027695A1 (de) 2001-04-19
WO2000073430A2 (de) 2000-12-07

Similar Documents

Publication Publication Date Title
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
WO2002080851A3 (en) Chimeric vaccines
PL392964A1 (pl) Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
SI1583774T1 (sl) Postopki za preprečevanje in zdravljenje Alzheimerjeve bolezni AD
EP1630229A3 (de) Melanoma Antigene
CA2325566A1 (en) Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
JP6466327B2 (ja) 免疫調節ワクチン
CN111440229A (zh) 新型冠状病毒t细胞表位及其应用
CN113329762A (zh) 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
WO2003042362A8 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
DE69716240T2 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
WO2005007673A3 (en) Immunogenic peptides
WO2006102901A3 (en) Immunogenic egfr peptides comprising foreign t cell stimulating epitope
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
WO2002016591A3 (en) Human transporter family members and uses thereof
ZA200602107B (en) Piroplasmid vaccine
WO2008078177A3 (en) Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2000044392A3 (en) Identification of specific differentially expressed mycobacterial antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2375033

Country of ref document: CA

Ref document number: 2375033

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000951201

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 64243/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09979958

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000951201

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000951201

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)